ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
63.38 USD   -0.66%
07/01Stifel Adjusts Ultragenyx Pharmaceutical's Price Target to $142 from $176, Keeps Buy Rating
MT
06/27ULTRAGENYX PHARMACEUTICAL INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/16TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-16-2022 10:00 AM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
60.24(c) 59.66(c) 62.65(c) 63.8(c) 63.38(c) Last
306 633 656 585 455 255 553 141 636 231 Volume
+2.57% -0.96% +5.01% +1.84% -0.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 373 M - -
Net income 2022 -512 M - -
Net cash position 2022 437 M - -
P/E ratio 2022 -8,70x
Yield 2022 -
Sales 2023 491 M - -
Net income 2023 -408 M - -
Net cash position 2023 366 M - -
P/E ratio 2023 -10,8x
Yield 2023 -
Capitalization 4 432 M 4 432 M -
EV / Sales 2022 10,7x
EV / Sales 2023 8,29x
Nbr of Employees 1 119
Free-Float 95,5%
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The... 
More about the company
Ratings of Ultragenyx Pharmaceutical Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ULTRAGENYX PHARMACEUTICAL INC.
07/01Stifel Adjusts Ultragenyx Pharmaceutical's Price Target to $142 from $176, Keeps Buy Ra..
MT
06/27ULTRAGENYX PHARMACEUTICAL INC. : Submission of Matters to a Vote of Security Holders (form..
AQ
06/16TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 43rd Annual Global H..
CI
06/10Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
GL
06/10Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
GL
06/08TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at 2022 Jefferies Global Healthcare C..
CI
06/01Ultragenyx to Present at Jefferies Global Healthcare Conference
GL
05/24Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Kee..
MT
05/19Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reit..
MT
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
GL
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
AQ
05/19Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two ..
CI
05/17Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Ther..
MT
05/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
More news
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.
06/17Astrazeneca prüft Übernahmeangebot für Mereo Biopharma - Zeitung
05/19Ultragenyx Pharmaceutical Inc. annonce des données positives sur la durabilité à plus l..
05/17Ultragenyx Pharmaceutical octroie une licence au traitement du syndrome de Sanfilippo d..
05/06MISE À JOUR SECTORIELLE : Soins de santé
05/05Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL affiche un chiffre d'affaires de 79,9 m..
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 63,38 $
Average target price 123,31 $
Spread / Average Target 94,6%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-24.63%4 432
GILEAD SCIENCES, INC.-13.61%78 683
VERTEX PHARMACEUTICALS32.59%74 466
REGENERON PHARMACEUTICALS, INC.-5.80%64 098
WUXI APPTEC CO., LTD.-4.67%49 112
BIONTECH SE-37.86%38 932